DexCom (NASDAQ:DXCM) Given “Buy” Rating at Truist Financial

DexCom (NASDAQ:DXCM)‘s stock had its “buy” rating reiterated by equities researchers at Truist Financial in a note issued to investors on Monday,Benzinga reports. They currently have a $82.00 price objective on the medical device company’s stock, down from their prior price objective of $94.00. Truist Financial’s price objective suggests a potential upside of 38.78% from the company’s previous close.

DXCM has been the topic of several other research reports. Oppenheimer downgraded DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Canaccord Genuity Group set a $99.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Friday. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Morgan Stanley boosted their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $84.00 target price on shares of DexCom in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $89.86.

DexCom Trading Up 1.5%

DXCM traded up $0.87 on Monday, hitting $59.09. The company had a trading volume of 3,731,576 shares, compared to its average volume of 4,329,758. DexCom has a 12-month low of $56.44 and a 12-month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $70.94 and its 200 day simple moving average is $78.02. The company has a market cap of $23.17 billion, a PE ratio of 41.28, a PEG ratio of 1.43 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. Equities research analysts expect that DexCom will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,383 shares of company stock worth $434,274 over the last quarter. Company insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DXCM. Andra AP fonden acquired a new position in shares of DexCom in the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in DexCom during the 2nd quarter worth about $26,000. SJS Investment Consulting Inc. grew its stake in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in DexCom in the first quarter valued at approximately $27,000. Finally, Financial Consulate Inc. acquired a new stake in DexCom during the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.